Moreover, even when prescribed, Hispanic and non-Hispanic Black individuals are more likely to report cost-prohibitive access barriers to diabetes medications, increasing risk in these populations for diabetes-related complications and mortality.[85] As future research aims to comprehensively assess the full scope of GLP-1RAs benefits and risks, it is imperative that such studies include the populations with the greatest potential for benefit and explore strategies to mitigate disparities in post-marketing access to these therapies.[86] CONCLUSIONS Since their introduction two decades ago, GLP-1RAs have expanded from glycemic control to treat a variety of conditions in individuals without diabetes, including weight management, cardiovascular risk reduction, and obstructive sleep apnea
Given the study did not show a significant difference in fibrosis stage, semaglutide has not yet been FDA approved for NASH
BPC-157 is one of our most popular treatments, and for good reason
GLP-1 receptor agonists are a class of medications that mimic the action of glucagon-like peptide-1, a naturally occurring hormone in the body
It also promotes healthy injection practices by assisting with site rotation, reducing the risk of tissue damage
Given the narrative nature of this review, a double-blind screening process was not applied, which is acknowledged as a limitation